Back
01 Apr 2025
AsiaMedic Limited Reports FY2024 Financial Results
Summary:
-
Revenue: Increased to S$11.2 million in FY2024, up from S$10.5 million in FY2023.
-
Net Profit: Achieved S$1.3 million, a significant improvement from a net loss of S$0.4 million in the previous year.
-
Earnings Per Share (EPS): Rose to 0.15 Singapore cents, compared to a loss per share of 0.05 cents in FY2023.
-
Total Assets: Increased to S$15.8 million as of 31 December 2024, from S$14.9 million a year earlier.
-
Total Liabilities: Decreased to S$4.2 million, down from S$5.1 million at the end of FY2023.
-
Cash and Cash Equivalents: Improved to S$3.5 million, up from S$2.8 million in the prior year.
Note: All data is sourced from AsiaMedic Limited's Annual Report for the financial year ended 31 December 2024.